- Home
- PNR vs INCY Comparison
PNR vs INCY Comparison
Compare PNR & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNR
- INCY
- Stock Information
- Founded
- PNR 1966
- INCY 1991
- Country
- PNR United Kingdom
- INCY United States
- Employees
- PNR N/A
- INCY N/A
- Industry
- PNR Industrial Machinery/Components
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- PNR Industrials
- INCY Health Care
- Exchange
- PNR Nasdaq
- INCY Nasdaq
- Market Cap
- PNR 17.4B
- INCY 17.0B
- IPO Year
- PNR N/A
- INCY 1993
- Fundamental
- Price
- PNR $106.35
- INCY $93.48
- Analyst Decision
- PNR Buy
- INCY Buy
- Analyst Count
- PNR 15
- INCY 20
- Target Price
- PNR $118.20
- INCY $84.50
- AVG Volume (30 Days)
- PNR 1.3M
- INCY 2.3M
- Earning Date
- PNR 10-21-2025
- INCY 10-28-2025
- Dividend Yield
- PNR 0.94%
- INCY N/A
- EPS Growth
- PNR N/A
- INCY 3878.02
- EPS
- PNR 3.93
- INCY 5.90
- Revenue
- PNR $4,128,399,999.00
- INCY $4,813,105,000.00
- Revenue This Year
- PNR $2.60
- INCY $16.45
- Revenue Next Year
- PNR $3.99
- INCY $10.93
- P/E Ratio
- PNR $27.06
- INCY $15.84
- Revenue Growth
- PNR 0.83
- INCY 18.09
- 52 Week Low
- PNR $74.25
- INCY $53.56
- 52 Week High
- PNR $113.95
- INCY $95.10
- Technical
- Relative Strength Index (RSI)
- PNR 38.87
- INCY 66.39
- Support Level
- PNR $108.15
- INCY $84.02
- Resistance Level
- PNR $110.12
- INCY $92.86
- Average True Range (ATR)
- PNR 2.90
- INCY 3.52
- MACD
- PNR -0.42
- INCY 0.46
- Stochastic Oscillator
- PNR 30.14
- INCY 86.03
About PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.